PURPOSE Biliary tract cancers (BTCs), particularly gallbladder carcinoma (GBC), are highly aggressive and exhibit significant geographical disparity, with a high incidence in Northern India. Human epidermal growth factor receptor 2 (HER2) amplification represents a key targetable alteration in a subset of patients. This study evaluates the real-world outcomes of trastuzumab in combination with chemotherapy for HER2-positive BTCs. METHODS A retrospective analysis of 91 patients with HER2-positive (immunohistochemistry 2+ amplified or 3+) BTCs was conducted. Patient characteristics and treatment details were summarized using descriptive statistics. The primary end points were progression-free survival (PFS) and overall survival (OS), estimated using the Kaplan-Meier method and compared with the log-rank test. RESULTS The median age was 50 years, with a female predominance (70.3%). Nearly all patients had GBC (98.9%) and HER2 3+ positivity (91.2%); 76.9% had metastatic disease. Trastuzumab was administered to 49 patients (53.8%), mostly in the first line (38.5%). The median PFS was 11.8 months (95% CI, 7.7 to 15.8) with trastuzumab versus 2.8 months (95% CI, 2.4 to 3.1) without ( P < .001). The median OS was 17.3 months (95% CI, 13.5 to 21.1) with trastuzumab versus 5.8 months (95% CI, 4.3 to 7.3) without ( P < .001). The 2-year OS rate was 32.7% for the trastuzumab group versus 11.8% for the control group. CONCLUSION In this real-world cohort from a high-incidence region, trastuzumab-based therapy was associated with a significant and clinically meaningful improvement in survival outcomes for HER2-positive BTCs. These findings strongly support routine HER2 testing and the integration of trastuzumab into the treatment arsenal for this molecularly defined subgroup.
Gupta et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: